Apotex’s section 8 claim for Apo-Atomoxetine dismissed

Start
On March 30, 2023, the Ontario Superior Court of Justice dismissed Apotex’s claim under section 8 of the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) relating to Apo-Atomoxetine (Lilly’s STRATTERA) and Canadian Patent No. 2,209,735 (735 patent): Apotex v Eli Lilly, 2023 ONSC 1968….
By: Smart & Biggar
Previous Story

Commercial banks’ obligation to maintain cyber resilience and security

Next Story

ChatUSG: What Companies Doing Business with the Government Need to Know About Artificial Intelligence